Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist

What Was Tested

Researchers studied Elagolix (non-peptide) in the context of endometriosis in this randomized controlled trial publication.

Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain.

Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppression in previous studies.

Who Took Part

The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, women only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Elagolix (non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Elagolix (non-peptide), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Elagolix (non-peptide) group a baseline to be compared against.

What Was Measured

Topics PubMed links to this paper include Bone Density, Dysmenorrhea, Endometriosis, Estrogen Antagonists, Gonadotropin-Releasing Hormone, Hot Flashes and Hydrocarbons, Fluorinated.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Elagolix (non-peptide) in people with endometriosis.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (The New England journal of medicine), a journal based in United States.

More context: the Elagolix (non-peptide) compound page, Endometriosis research.